The company plans to use the money to expand—adding laboratories in Texas, Florida and Arizona—as well as grow its research on skin care diagnostics. PathologyWatch is also working on artificial intelligence technology that could help diagnose patients, once it gains Food and Drug Administration approval. The number of skin samples sent to the startup’s laboratories have quadrupled over the last year, Dan Lambert, CEO and cofounder told Crunchbase News.
“As digital dermatopathology continues to grow, it has the potential to reduce the costs of pathology by billions while creating better patient care for everyone across the country,” Lambert said in a statement. “We’re thrilled to be winning so much volume so quickly.”
PathologyWatch’s platform includes its private laboratories where tests on patient biopsies can be prepared, evaluated by pathologists and scanned with reports on the findings that are accessible online at all times. The result is a more...
learn more
